Daiichi Sankyo invests $150 million to establish a new antibody-drug conjugate manufacturing facility in Shanghai by 2030, ...

In tandem with Enhertu’s inclusion in China’s national insurance program, Daiichi Sankyo is planting a foothold in local ...

Elevation Oncology has tapped Lonza’s Synaffix to support the expansion of its pipeline, agreeing to pay up to $368 million ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/91.IM06wodO.js ...

Daiichi Sankyo begins patient dosing in QuANTUM-Wild phase 3 trial of Vanflyta in newly diagnosed FLT3-ITD negative AML: Tokyo Thursday, December 12, 2024, 12:00 Hrs [IST] The fir ...

AstraZeneca AZN and its Japanese partner Daiichi Sankyo announced that the FDA has granted a Breakthrough Therapy designation ...

此次FDA授予突破性疗法认定主要是基于TROPION-Lung05临床2期试验数据，并加上TROPION-Lung01临床3期试验的支持性数据。今年美国临床肿瘤学会（ASCO）年会中所公布的TROPION-Lung05试验的部分结果显示，18名具有目 ...

Developed alongside AstraZeneca, the breakthrough designation comes following early pooled results from two ongoing trials ...

The new 1.1 billion-yuan ($152 million) production facility in Shanghai will make antibody-drug conjugates, which use ...

IHH Healthcare, Asia's largest private healthcare group headquartered in Malaysia, has initiated legal action against Japan's Daiichi Sankyo, seeking damages for alleged ...